AbCellera Biologics downgraded by The Benchmark Company
$ABCL
Pharmaceuticals and Biotechnology
Health Care
The Benchmark Company downgraded AbCellera Biologics from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2024 | Buy → Hold | The Benchmark Company | |
| 2/22/2024 | $9.00 | Hold → Buy | The Benchmark Company |
| 12/5/2023 | $6.00 | Overweight | KeyBanc Capital Markets |
| 11/6/2023 | Buy → Hold | The Benchmark Company | |
| 10/13/2023 | $20.00 | Overweight | Piper Sandler |
| 2/28/2023 | Outperform | Cowen | |
| 12/15/2022 | $30.00 | Buy | Goldman |
| 11/16/2022 | $29.00 | Buy | Truist |
AbCellera (NASDAQ:ABCL) today announced that executives from the Company will present at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference in New York, NY on Tuesday, December 3, 2024, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025, at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time) Live audio webcasts of the presentation may be accessed through the link that will be posted on AbCellera's Investor Relations website. Replays of the webcast will be available through the same links following the presentations. About AbCellera Biologics Inc. AbCel
AbCellera (NASDAQ:ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the George R. Brown Convention Center in Houston, Texas. AbCellera's presentation, which is available for viewing here, describes: Strategies to address key challenges in TCE development: CD3-binding antibodies to widen the therapeutic window by generating TCEs with potent tumor-cell killing and optimal cytokine release Molecules to enhance efficacy for solid tumor indications by increasing T-cell activation and proliferation through costimulation of CD28 and 4-1BB Application of the platform to tw
AbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical trials activities in 2025 and beyond," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Notably, we completed the consolidation into our new headquarters in Vancouver, Canada, which marks a significant milestone towards completing our platform and infrastructure investments." Q3 2024 Business Summary Expanded existing collaboration with E
SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)
SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)
SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
4 - AbCellera Biologics Inc. (0001703057) (Issuer)
AbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "Through the third quarter we continued to execute on our key priorities of advancing our internal pipeline and building capabilities to support clinical trials activities in 2025 and beyond," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Notably, we completed the consolidation into our new headquarters in Vancouver, Canada, which marks a significant milestone towards completing our platform and infrastructure investments." Q3 2024 Business Summary Expanded existing collaboration with E
AbCellera (NASDAQ:ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data
AbCellera (NASDAQ:ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "This quarter, we made important progress on our internal pipeline and aim to submit applications for clinical trials for ABCL635 and ABCL575 in the second quarter of 2025. In parallel, we have focused preclinical work on our T-cell engager platform to four molecules for indications in oncology and autoimmunity," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Since our last earnings release, two of our partners have achieved notable milestones, including Abdera's IND clearance and Fast Tr
AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir
TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev
AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d
The Benchmark Company downgraded AbCellera Biologics from Buy to Hold
The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $9.00
KeyBanc Capital Markets initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $6.00
10-Q - AbCellera Biologics Inc. (0001703057) (Filer)
8-K - AbCellera Biologics Inc. (0001703057) (Filer)
SCHEDULE 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)
Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and lowers the price target from $7 to $5.
Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and lowers the price target from $8 to $7.
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $9.954 million which missed the analyst consensus estimate of $10.836 million by 8.14 percent. This is a 18.36 percent decrease over sales of $12.192 million the same period last year.